PATENT CLAIM ANALYSIS

Application Number: 16310918
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-05
Patent Classification: ["546", "193000"]

Abstract:
The invention provides compounds of formula I or pharmaceutically acceptable salt, solvate or hydrate thereof (I) wherein ring A represents group A-I or A-II (A-I, A-II) A1, A2, A3, A4 represent independently C(R4aa) or N, wherein no more than one of A1, A2, A3, and A4 represents N; A5 represents C(R4b) or N; B1, B2, B3 and B4 represent independently C(R3) or N, wherein no more than two of B1, B2, B3 and B4 represent N; n is 1 or 2; and R1, R2, R3, R4a and R4aa and R4b are as defined in the claims, as well as methods of using the compounds to treat proliferation diseases, in particular cancer.

Claim (Index 1):
A compound of formula I: or a pharmaceutically acceptable salt, solvate or hydrate thereof, wherein: ring A represents group A-I or A-II A1, A2, A3, A4 represent independently C(R4aa) or N, wherein no more than one of A1, A2, A3, and A4 represents N; A5 represents C(R4b) or N; B1, B2, B3 and B4 represent independently C(R3) or N, wherein no more than two of B1, B2, B3 and B4 represent N; T represents >N\u2014, >C\u2550 or >CH\u2014 when ring A represents group A-I; T represents >C\u2550 or >CH\u2014 when ring A represents group A-II; X represents \u2014C(R6a)(R6b)-, \u2014C(R6a)=, \u2014O\u2014, \u2014S\u2014 or \u2014C(O)\u2014, providing that X is not \u2014C(O)\u2014, \u2014O\u2014 or \u2014S\u2014 when T is >N\u2014; R1 represents independently at each occurrence halogen, cyano, hydroxyl, \u2014N(R5a)(R5b), C1-C6alkyl, C1-C6haloalkyl or C1-C6alkyl wherein one or two carbon atoms are independently replaced by \u2014O\u2014 or \u2014N(R5a)- and wherein the alkyl moiety is optionally substituted by one or more halogen; R2 represents halogen, cyano, hydroxyl, mercapto, C1-C6alkyl optionally substituted by one to five R14, C2-C6alkenyl optionally substituted by one to five R14, C2-C6alkynyl optionally substituted by one to five R14, C1-C6alkoxy optionally substituted by one to five R14, \u2014N(R9a)(R9b), \u2014C1-C6alkylene-N(R9a)(R9b), \u2014CHO, \u2014C1-C6alkylene-CHO, \u2014C(O)OR10, \u2014C1-C6alkylene-C(O)OR10, \u2014C(O)N(R11a)(R11b), \u2014C1-C6alkylene-C(O)N(R11a)(R11b), \u2014N(R12)C(O)R13, \u2014C1-C6alkylene-N(R12)C(O)R13, C1-C6alkylthio, C1-C6alkylsulfinyl, C1-C6alkylsulfonyl, Cycle-P, \u2014C1-C6alkylene-Cycle-P, Cycle-Q or \u2014C1-C6alkylene-Cycle-Q; R3 represents independently at each occurrence hydrogen, halogen, cyano, C1-C4alkyl, C1-C4haloalkyl, C1-C4alkoxy, C1-C4haloalkoxy or \u2014N(R8a)(R8b); R4a and R4b represent independently hydrogen, amino, \u2014NH(C1-C4alkyl), \u2014N(C1-C4alkyl) 2  or \u2014C1-C4alkylene-R4c; R4aa represents independently at each occurrence hydrogen, amino, \u2014NH(C1-C4alkyl), \u2014N(C1-C4alkyl) 2 , \u2014C1-C4alkylene-R4c or C3-C4cycloalkyl; R4c represents independently at each occurrence hydrogen, cyano, hydroxyl, amino, C1-C4alkoxy, \u2014CONH 2 , \u2014NH(C1-C4alkyl), \u2014N(C1-C4alkyl) 2 , Cycle-P or Cycle-Q; R5a and R5b represent independently at each occurrence hydrogen or C1-C6alkyl; R6a and R6b represent independently hydrogen or C1-C4alkyl; each R8a and R8b represents independently at each occurrence hydrogen or C1-C4alkyl; R9a represents hydrogen, C1-C6alkyl optionally substituted by one to five R14, \u2014C1-C6alkylene-Cycle-P, \u2014C1-C6alkylene-Cycle-Q, Cycle-P or Cycle-Q; R9b, R11a, R11b and R12 represent independently hydrogen or C1-C6alkyl; R10 and R13 represent independently at each occurrence C1-C6alkyl; R14 represents independently at each occurrence halogen, cyano, hydroxyl, C1-C6alkoxy, amino, \u2014NH(C1-C4alkyl), \u2014N(C1-C4alkyl) 2  or \u2014N(R12)C(O)R13; Cycle-P represents independently at each occurrence a saturated or partially unsaturated 3- to 8-membered carbocyclic ring optionally substituted by 1 to 3 R16, or a saturated or partially unsaturated 3- to 8-membered heterocyclic ring optionally substituted by 1 to 3 R16 containing carbon atoms as ring members and one or two ring members independently selected from N and O, wherein N optionally may bear R15; Cycle-Q represents independently at each occurrence phenyl optionally substituted by 1 to 3 R17 or a 5- to 6-membered heteroaryl ring containing one to four heteroatoms selected from O, S and N, optionally substituted by 1 to 3 R17; R15 represents independently at each occurrence hydrogen or C1-C4alkyl; R16 and R17 represent independently at each occurrence cyano, C1-C4alkyl, C1-C4haloalkyl, C1-C4alkoxy or C1-C4haloalkoxy; n is 1 or 2; and q is 0, 1, 2, 3 or 4; and wherein the compound is not the following compounds:\n 1-Piperidinecarboxamide, 4-[(4-fluorophenyl)methyl]-N-(3-methyl]-N-1,2,4-thiadiazol-5-yl)-; \n 1-Piperidinecarboxamide, 4-(4-fluorobenzoyl)-N-(2-methyl-4-pyridinyl)-; \n and wherein the compound is optionally not the following compound:\n 1-Piperidinecarboxamide, 4-(4-chlorobenzoyl)-N-4-pyridinyl-.

Metadata:
- Claim Count in Document: 14.0
- Percentile: 98.0
- Lexical Diversity: 2.11429
- Patent Class: 546.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15580008', '15545149', '13145323', '14552853', '14216486']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8158526105954403
- 35 USC 102 Novelty (BERT): 0.5392337635847301
- Combined Prediction Score: 0.7881907258943693
- Mean Citation Score: 361.492284
- Max Citation Score: 388.39368
- Similarity Product: 275.249091781497

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test